High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation

Chen,Weihua; Delongchamps,Nicolas Barry; Mao,Kaili; Beuvon,Frédéric; Peyromaure,Michaël; Liu,Zhongmin; Dinh‑Xuan,Anh  Tuan

doi:10.3892/ol.2015.4070

High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation

Authors:
- Weihua Chen
- Nicolas Barry Delongchamps
- Kaili Mao
- Frédéric Beuvon
- Michaël Peyromaure
- Zhongmin Liu
- Anh Tuan Dinh‑Xuan
View Affiliations

Affiliations: Department of Urology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China, Department of Urology, Cochin Hospital, Paris Descartes University, Paris 75014, France, Department of Pathology, Cochin Hospital, Paris Descartes University, Paris 75014, France, Clinical and Translational Research Center, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China, Department of Functional Physiology, School of Medicine, Cochin Hospital, Paris Descartes University, Paris 75014, France
Published online on: December 31, 2015 https://doi.org/10.3892/ol.2015.4070
Pages: 1375-1381
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ras homolog gene family, member A (RhoA) has been reported as essential to the invasion process and aggressiveness of numerous cancers. However, there are only sparse data on the expression and activity of RhoA in clinically localised prostate cancer. In numerous cancers, tumour cells at the invasive front demonstrate more aggressive behaviour in comparison with the cells in the central regions. In the present study, the expression and activity of RhoA was evaluated in 34 paraffin‑embedded and 20 frozen prostate tissue specimens obtained from 45 patients treated with radical prostatectomy for clinically localised cancer. The expression patterns of RhoA were assessed by immunohistochemical staining and western blotting. Additional comparisons were performed between the tumour centre, tumour front and distant peritumoural tissue. RhoA activity was assessed by G‑LISA. Associations between RhoA expression and the clinical features and outcome of the patients were also analysed. The present study found an increasing gradient of expression from the centre to the periphery of index tumour foci. RhoA expression was significantly increased at the tumour front compared to the tumour centre, which was determined using immunohistochemistry (P=0.001). Increased RhoA expression was associated with poor tumour differentiation in the tumour front (P=0.044) and tumour centre (P=0.039). Subsequent to a median follow‑up period of 52 months, the rate of prostate‑specific antigen (PSA) relapse was increased in patients with higher RhoA expression at the tumour front when compared with patients with lower RhoA expression (62.5 vs. 35.0%), although the difference was not significant (P=0.09). There was no association between RhoA expression and the PSA level or pathological stage in the present study. In conclusion, RhoA expression was increased at the tumour front and was associated with poor tumour differentiation in the tumour front and tumour centre, indicating the potential role of RhoA in prostate cancer. RhoA expression may also act as a prognostic factor in prostate cancer. The present data provide a foundation for novel therapeutic approaches by targeting RhoA in prostate cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H and de la Roza G: Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 99:1484–1489. 2007. View Article : Google Scholar : PubMed/NCBI
3	Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH and Tulinius H: Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 20:680–688. 1977. View Article : Google Scholar : PubMed/NCBI
4	Thompson IM: Latent carcinoma of the prostate. Eur Urol. 39(Suppl 4): S41–S42. 2001. View Article : Google Scholar
5	Stamey TA, Yemoto CM, McNeal JE, Sigal BM and Johnstone IM: Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol. 163:1155–1160. 2000. View Article : Google Scholar : PubMed/NCBI
6	Gulati R, Wever EM, Tsodikov A, Penson DF, Inoue LY, Katcher J, Lee SY, Heijnsdijk EA, Draisma G, de Koning HJ and Etzioni R: What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev. 20:740–750. 2011. View Article : Google Scholar : PubMed/NCBI
7	Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS, et al: Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol. 179:400–410. 2011. View Article : Google Scholar : PubMed/NCBI
8	Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ and Schalken P: Cadherin switching in human prostate cancer progression. Cancer Res. 60:3650–3654. 2000.PubMed/NCBI
9	Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H and Mikulits W: Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutat Res. 566:9–20. 2004. View Article : Google Scholar : PubMed/NCBI
10	Pertz O, Hodgson L, Klemke RL and Hahn KM: Spatiotemporal dynamics of RhoA activity in migrating cells. Nature. 440:1069–1072. 2006. View Article : Google Scholar : PubMed/NCBI
11	Machacek M, Hodgson L, Welch C, Elliott H, Pertz O, Nalbant P, Abell A, Johnson GL, Hahn KM and Danuser G: Coordination of Rho GTPase activities during cell protrusion. Nature. 461:99–103. 2009. View Article : Google Scholar : PubMed/NCBI
12	Kurokawa K and Matsuda M: Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Biol Cell. 16:4294–4303. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet L, Camonis J, D'Souza-Schorey C and Chavrier P: The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol. 181:985–998. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hotary K, Li XY, Allen E, Stevens SL and Weiss SJ: A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 20:2673–2686. 2006. View Article : Google Scholar : PubMed/NCBI
15	Berton S, Belletti B, Wolf K, Canzonieri V, Lovat F, Vecchione A, Colombatti A, Friedl P and Baldassarre G: The tumor suppressor functions of p27(kip1) include control of the mesenchymal/amoeboid transition. Mol Cell Biol. 29:5031–5045. 2009. View Article : Google Scholar : PubMed/NCBI
16	Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T and Konishi I: Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest. 83:861–870. 2003. View Article : Google Scholar : PubMed/NCBI
17	Modolo F, Biz MT, de Sousa SM, Fachinelli Rde L and Crema VO: Immunohistochemical expression of Rho GTPases in ameloblastomas. J Oral Pathol Med. 41:400–407. 2012. View Article : Google Scholar : PubMed/NCBI
18	Fritz G, Brachetti C, Bahlmann F, Schmidt M and Kaina B: Rho GTPases in human breast tumours: Expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 87:635–644. 2002. View Article : Google Scholar : PubMed/NCBI
19	Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, et al: RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol. 26:716–735. 2012. View Article : Google Scholar : PubMed/NCBI
20	Epstein JI, Allsbrook WC Jr, Amin MB and Egevad LL: ISUP Grading Committee: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 29:1228–1242. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sobin LH, Gospodarowicz MK and Wittekind C: Prostate. TNM Classification of Malignant Tumors (7th). (Hoboken, NJ). 243–248. 2009.
22	Taylor CR and Levenson RM: Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology. 49:411–424. 2006. View Article : Google Scholar : PubMed/NCBI
23	Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A and Lindholm PF: Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res. 63:1359–1364. 2003.PubMed/NCBI
24	Zheng R, Iwase A, Shen R, Goodman OB Jr, Sugimoto N, Takuwa Y and Lerner DJ: Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene. 25:5942–5952. 2006. View Article : Google Scholar : PubMed/NCBI
25	Loberg RD, Tantivejkul K, Craig M, Neeley CK and Pienta KJ: PAR1-mediated RhoA activation facilitates CCL2-induced chemotaxis in PC-3 cells. J Cell Biochem. 101:1292–1300. 2007. View Article : Google Scholar : PubMed/NCBI
26	Chen X, Corbin JM, Tipton GJ, Yang LV, Asch AS and Ruiz-Echevarría MJ: The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells. Biochim Biophys Acta. 1843:1216–1224. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G and Dahiya R: MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One. 7:e297222012. View Article : Google Scholar : PubMed/NCBI
28	Grandoch M, Rose A, ter Braak M, Jendrossek V, Rübben H, Fischer JW, Schmidt M and Weber P: Epac inhibits migration and proliferation of human prostate carcinoma cells. Br J Cancer. 101:2038–2042. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zhou C, Ling MT, Lee Kin-Wah T, Man K, Wang X and Wong YC: FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 233:36–47. 2006. View Article : Google Scholar : PubMed/NCBI
30	Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL and Campbell WB: Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. Endocrinology. 153:29–41. 2012. View Article : Google Scholar : PubMed/NCBI
31	Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell. 7:513–520. 2005. View Article : Google Scholar : PubMed/NCBI
32	Cianchi F, Cuzzocrea S, Vinci MC, Messerini L, Comin CE, Navarra G, Perigli G, Centorrino T, Marzocco S, Lenzi E, et al: Heterogeneous expression of cyclooxygenase-2 and inducible nitric oxide synthase within colorectal tumors: Correlation with tumor angiogenesis. Dig Liver Dis. 42:20–27. 2010. View Article : Google Scholar : PubMed/NCBI
33	Delongchamps NB, Beuvon F, Mathieu JR, Delmas S, Metzger I, Prats H and Cabon F: CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers. World J Urol. 33:281–287. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gasman S, Chasserot-Golaz S, Hubert P, Aunis D and Bader MF: Identification of a potential effector pathway for the trimeric Go protein associated with secretory granules. Go stimulates a granule-bound phosphatidylinositol 4-kinase by activating RhoA in chromaffin cells. J Biol Chem. 273:16913–16920. 1998. View Article : Google Scholar : PubMed/NCBI
35	Frantz C, Coppola T and Regazzi R: Involvement of Rho GTPases and their effectors in the secretory process of PC12 cells. Exp Cell Res. 273:119–126. 2002. View Article : Google Scholar : PubMed/NCBI